Past 10 year's financial track record analysis by Moneyworks4me indicates that Titan Bio-Tech Ltd is a average quality company.
The key valuation ratios of Titan Bio-Tech Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Titan Bio-Tech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 13.6% | 12% | 12.7% | 12.9% | 12.5% | 18.6% | 61.6% | 35.5% | 27.9% | 26.3% | - |
| Value Creation Index ⓘ | 0.0 | -0.2 | -0.1 | -0.1 | -0.1 | 0.3 | 3.4 | 1.5 | 1.0 | 0.9 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 40.3 | 45.6 | 52.5 | 55.5 | 58.2 | 69.5 | 122 | 124 | 144 | 164 | 169 |
| Sales YoY Gr. | - | 13.1% | 15% | 5.9% | 4.9% | 19.3% | 76.3% | 0.9% | 16.6% | 13.9% | - |
| Adj EPS ⓘ | 2.2 | 2.2 | 2.9 | 2.8 | 3.3 | 6.7 | 34.7 | 26.2 | 25.4 | 28.2 | 27.8 |
| YoY Gr. | - | 3.2% | 31.4% | -6.1% | 18.9% | 105.2% | 416.4% | -24.3% | -3.2% | 10.9% | - |
| BVPS (₹) ⓘ | 26.5 | 27.8 | 29.9 | 31.4 | 38.3 | 45.8 | 79.7 | 104.4 | 128.4 | 155.4 | 166.5 |
| Adj Net Profit ⓘ | 1.7 | 1.7 | 2.3 | 2.1 | 2.7 | 5.5 | 28.6 | 21.7 | 21 | 23.3 | 23 |
| Cash Flow from Ops. ⓘ | -1.8 | 4.9 | 0 | 1.6 | 6.2 | 6.9 | 17.6 | 22 | 21.2 | 21.2 | - |
| Debt/CF from Ops. ⓘ | -4.3 | 2.3 | -579.6 | 16.3 | 3.5 | 2.6 | 0.5 | 0.3 | 0.3 | 0.3 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 16.9% | 23% | 10.2% | 13.9% | ||||
| Adj EPS ⓘ | 33% | 53.8% | -6.7% | 10.9% | ||||
| BVPSⓘ | 21.7% | 32.3% | 25% | 21.1% | ||||
| Share Price | 36.9% | 78.7% | 35% | 78.2% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 9.3 | 8.2 | 10.2 | 9 | 9.7 | 16 | 55.3 | 28.5 | 21.8 | 19.8 | 17.2 |
| Op. Profit Mgn % ⓘ | 9.8 | 8.8 | 10.5 | 11.9 | 12.9 | 15.7 | 34.2 | 25.3 | 20.5 | 20.9 | 19.9 |
| Net Profit Mgn % ⓘ | 4.1 | 3.8 | 4.3 | 3.8 | 4.6 | 8 | 23.4 | 17.6 | 14.6 | 14.2 | 13.6 |
| Debt to Equity ⓘ | 0.4 | 0.5 | 1 | 1 | 0.7 | 0.5 | 0.1 | 0.1 | 0.1 | 0.1 | 0 |
| Working Cap Days ⓘ | 154 | 155 | 147 | 175 | 192 | 185 | 150 | 189 | 175 | 168 | 92 |
| Cash Conv. Cycle ⓘ | 115 | 114 | 111 | 140 | 156 | 147 | 102 | 125 | 122 | 122 | 68 |
Sales growth is growing at healthy rate in last 3 years 10.24%
Sales growth is good in last 4 quarters at 18.98%
Return on Equity has declined versus last 3 years average to 17.20%
Net Profit has been subdued in last 3 years -6.68%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 27.8 | 30.6 |
| TTM Sales (₹ Cr.) | 169 | 169 |
| BVPS (₹.) ⓘ | 166.5 | 175.4 |
| Reserves (₹ Cr.) ⓘ | 129 | 137 |
| P/BV ⓘ | 4.39 | 4.16 |
| PE ⓘ | 26.33 | 23.90 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 400.10 / 1017.85 |
| All Time Low / High (₹) | 1.05 / 1017.85 |
| Market Cap (₹ Cr.) | 604 |
| Equity (₹ Cr.) | 8.3 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 57.2 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 46 | 52 | 56 | 58 | 69 | 122 | 124 | 144 | 164 |
| Operating Expenses ⓘ | 36 | 42 | 47 | 49 | 51 | 59 | 81 | 92 | 114 | 130 |
| Manufacturing Costs | 5 | 5 | 7 | 7 | 7 | 8 | 15 | 13 | 17 | 19 |
| Material Costs | 25 | 30 | 33 | 31 | 31 | 36 | 49 | 58 | 70 | 76 |
| Employee Cost | 3 | 3 | 3 | 6 | 8 | 9 | 11 | 14 | 18 | 24 |
| Other Costs ⓘ | 3 | 4 | 4 | 5 | 5 | 5 | 6 | 7 | 10 | 11 |
| Operating Profit ⓘ | 4 | 4 | 6 | 7 | 7 | 11 | 42 | 31 | 30 | 34 |
| Operating Profit Margin (%) | 9.6% | 8.7% | 10.5% | 11.9% | 12.8% | 15.7% | 34.2% | 25.3% | 20.5% | 20.9% |
| Other Income ⓘ | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 2 |
| Interest ⓘ | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 2 | 3 | 3 | 4 | 4 | 8 | 39 | 29 | 28 | 32 |
| Tax ⓘ | 1 | 1 | 1 | 1 | 1 | 2 | 10 | 7 | 7 | 8 |
| Profit After Tax | 2 | 2 | 2 | 2 | 3 | 6 | 29 | 22 | 21 | 24 |
| PAT Margin (%) | 4.0% | 3.8% | 4.5% | 4.3% | 5.3% | 8.9% | 23.5% | 17.6% | 14.6% | 14.4% |
| Adjusted EPS (₹) | 2.1 | 2.2 | 3.0 | 3.1 | 3.7 | 7.5 | 34.8 | 26.2 | 25.4 | 28.6 |
| Dividend Payout Ratio (%) | 36% | 34% | 25% | 24% | 0% | 13% | 4% | 6% | 7% | 7% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 20 | 21 | 23 | 24 | 32 | 38 | 66 | 86 | 106 | 128 |
| Share Capital ⓘ | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves ⓘ | 13 | 14 | 15 | 17 | 23 | 30 | 58 | 78 | 98 | 120 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 8 | 11 | 22 | 25 | 21 | 17 | 8 | 6 | 6 | 7 |
| Long Term Debt | 2 | 4 | 15 | 17 | 12 | 8 | 2 | 1 | 0 | 0 |
| Short Term Debt | 6 | 7 | 7 | 7 | 9 | 8 | 6 | 5 | 6 | 6 |
| Trade Payables | 1 | 2 | 1 | 1 | 2 | 4 | 3 | 4 | 6 | 3 |
| Others Liabilities ⓘ | 4 | 4 | 4 | 6 | 6 | 8 | 20 | 19 | 20 | 21 |
| Total Liabilities ⓘ | 34 | 39 | 50 | 56 | 61 | 67 | 96 | 115 | 138 | 159 |
Fixed Assets | ||||||||||
| Gross Block | 16 | 17 | 18 | 19 | 34 | 35 | 39 | 49 | 52 | 71 |
| Accumulated Depreciation | 6 | 6 | 7 | 8 | 8 | 10 | 12 | 14 | 17 | 19 |
| Net Fixed Assetsⓘ | 11 | 10 | 11 | 11 | 26 | 25 | 27 | 35 | 36 | 52 |
| CWIP ⓘ | 1 | 5 | 9 | 13 | 0 | 0 | 0 | 4 | 13 | 3 |
| Investmentsⓘ | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 12 | 23 |
| Inventories | 11 | 11 | 14 | 17 | 20 | 24 | 27 | 35 | 36 | 46 |
| Trade Receivables | 6 | 6 | 6 | 8 | 8 | 11 | 16 | 16 | 21 | 19 |
| Cash Equivalents | 0 | 3 | 4 | 1 | 2 | 2 | 5 | 7 | 5 | 3 |
| Others Assetsⓘ | 4 | 4 | 4 | 4 | 4 | 4 | 19 | 15 | 15 | 15 |
| Total Assets ⓘ | 34 | 39 | 50 | 56 | 61 | 67 | 96 | 115 | 138 | 159 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -2 | 5 | 0 | 2 | 6 | 7 | 18 | 22 | 21 | 21 |
| PBT ⓘ | 2 | 3 | 3 | 4 | 4 | 8 | 39 | 29 | 28 | 32 |
| Adjustment ⓘ | 2 | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 4 | 5 |
| Changes in Working Capital ⓘ | -5 | 1 | -5 | -5 | -1 | -4 | -15 | -3 | -3 | -7 |
| Tax Paid ⓘ | -1 | -1 | -1 | -1 | -1 | -2 | -10 | -7 | -7 | -8 |
| Cash Flow From Investing Activity ⓘ | -3 | -5 | -7 | -5 | -4 | -1 | -4 | -16 | -21 | -20 |
| Capex | -2 | -4 | 0 | -5 | -4 | -1 | -4 | -14 | -4 | -19 |
| Net Investments | 0 | -1 | -6 | 0 | 0 | 0 | 0 | -3 | -8 | -12 |
| Others ⓘ | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10 | 11 |
| Cash Flow From Financing Activityⓘ | 3 | 2 | 8 | 0 | -2 | -6 | -10 | -4 | -2 | -3 |
| Net Proceeds from Shares ⓘ | 4 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 1 | 4 | 11 | 3 | -5 | -4 | -7 | -1 | -1 | 0 |
| Interest Paid ⓘ | -1 | -1 | -1 | -2 | -2 | -2 | -1 | -1 | -1 | -1 |
| Dividend Paid ⓘ | -1 | -1 | -1 | -1 | 0 | 0 | -1 | -1 | -1 | -1 |
| Others ⓘ | 0 | 0 | 0 | 0 | 2 | 0 | -1 | -1 | 0 | 0 |
| Net Cash Flow ⓘ | -2 | 2 | 2 | -3 | 1 | 0 | 4 | 2 | -2 | -2 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 9.12 | 8.21 | 10.47 | 10.13 | 11.01 | 17.85 | 55.53 | 28.52 | 21.86 | 20.18 |
| ROCE (%) | 13.63 | 11.95 | 12.71 | 12.92 | 12.5 | 18.63 | 61.63 | 35.48 | 27.9 | 26.3 |
| Asset Turnover Ratio | 1.38 | 1.35 | 1.25 | 1.06 | 1 | 1.09 | 1.51 | 1.17 | 1.14 | 1.1 |
| PAT to CFO Conversion(x) | -1 | 2.5 | 0 | 1 | 2 | 1.17 | 0.62 | 1 | 1 | 0.88 | Working Capital Days |
| Receivable Days | 52 | 46 | 39 | 46 | 50 | 48 | 40 | 48 | 47 | 44 |
| Inventory Days | 77 | 82 | 83 | 102 | 116 | 116 | 76 | 91 | 90 | 91 |
| Payable Days | 21 | 19 | 16 | 13 | 19 | 28 | 23 | 22 | 25 | 22 |
Titan Biotech was established in 1992 with an objective of serving the scientific community and mankind by way of providing good quality of biological products i.e. protein hydrolysis, peptones and their derivatives, extracts, dehydrated microbiological culture media, plant tissue culture media and laboratory chemicals.
All the biological products are basically conducive to the growth of microorganisms and their primary use is in the development and growth of microorganisms in clinical diagnosis, production of vaccines, antibiotics and antisera, antimicrobial susceptibility testing to antibiotics, checking the bacterial contamination in food & water samples in departments of microbiology and relevant fields of science in medical colleges/universities/industries and tissue culture laboratories.
The company has developed more than 1700 Dehydrated Culture Media, Media Bases, and special type of Peptones and Hydrolysates for vaccine production and other uses. Titan uses the basic raw material i.e. Meet, Bile, Liver Blood, Brain, Heart and other parts of the animals in its process procured from the slaughter houses and other vegetable products like soya and casein, etc. converting them into free flowing powder to produce peptones, extracts and hydrolysates which are further used in manufacturing of dehydrated culture media and as raw material in pharmaceutical, health products and other Industries.
Recently it has introduced a wide range of chromomeric / fluorogenic culture media that does not require any further identification tests. This time they are introducing a range of vegetable culture media, which are animal free and possess equivalent growth characteristics to the Culture media that use animal peptones.
Besides these biological products, it also has a range of laboratory chemicals, analytical reagents, stains and indicators and Readymade stain kits. These materials are used in laboratories to carry out various tests and research work.
The company also manufactures wide range of plant growth promotor and its various basic ingredients, hormones, minerals and vitamins premixes as well as amino acid in liquid, powder and granular forms. Itd product Aminofert has become very popular among the users. The basic raw materials of this product are mixtures of amino acids, minerals and vitamins. It gives complete nourishment and helps in growth and productivity.
Product range of the company includes:
Culture Media & Supplements
Plant Tissue Culture
Lab Chemicals & Reagents
Bulk Products
Achievements/ recognition:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
